Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Castagna, Antonella; Maggiolo, Franco; Penco, Giovanni; P. Wright, David; Mills, Anthony; Grossberg, Robert; Molina, Jean‐Michel; Chas, Julie; Durant, J.; Moreno, Santiago; Doroana, Manuela; Ait‐Khaled, Mounir; Huang, J.; Min, Sherene; Song, Ivy; Vavro, Cindy; Nichols, Garrett; Yeo, Jane; the VIKING-3 Study Group, for; A. Aberg, Judith; Akil, Bisher; Ramón Arribas, José; Baril, J.G.; L. Blanco Arevalo, J.; Blanco Quintana, F.; Blick, Gary; Boix Martínez, Vicente; Bouchaud, Olivier; Branco, Teresa; Fritz Bredeek, U.; C. IGLESIAS, MANUEL; Clumeck, Nathan; Conway, Brian; DeJesus, E; L. Delassus, Jean; de Truchis, P.; Di Perri, Giovanni; Di Pietro, Massimo; Duggan, Joan; Duvivier, Claudine; Elion, Richard; Eron, Joseph; N. Fish, Douglas; Gathe, Joseph; Haubrich, Richard; Henderson, Heather; B. Hicks, Charles; Hocqueloux, Laurent; Hodder, Sally; Hsiao, CB; Katlama, Christine; J. Kozal, Michael; Kumar, Princy; N. Lalla-Reddy, Sujata; Lazzarin, Adriano; Leoncini, F; M. Llibre, Josep; Mansinho, Kamal; Morlat, Philippe; Mounzer, Karam; Murphy, M.; Newman, C.; Nguyen, Thuy; Nseir, Bacel; Philibert, Patrick; Pialoux, Gilles; Poizot‐Martin, Isabelle; Ramgopal, Moti; Richmond, Gary; Salmon Ceron, Dominique; E. Sax, Paul; Scarsella, A.; Sension, Michael; Shalit, Peter; Sighinolfi, L; Sloan, Louis; B. Small, Catherine; Stein, David; Tashima, K.; Tebas, Pablo; Torti, Carlo; Tribble, Marc; Troisvallets, Didier; Tsoukas, Christos; Viciana Fernandez, Pompeyo; Ward, Derek; P. Wheeler, Darrell; Wilkin, Timothy; Yeni, Guy-Patrick; Louise Martin-Carpenter, J.; Uhlenbrauck, G.

doi:10.1093/infdis/jiu051

Public

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Published in The Journal of Infectious Diseases • Jan 19, 2014

Authors:

Antonella Castagna

Franco Maggiolo

Giovanni Penco

Abstract

BACKGROUND: The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. METHODS: VIKING-3 is a single-arm, open-label phase III study in which t...

Subject

Elvitegravir

Dolutegravir

Raltegravir

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!